Nitric Oxide Mediates Cell Aggregation and Mesenchymal to Epithelial Transition in Anoikis-resistant Lung Cancer Cells
Overview
Authors
Affiliations
Cancer cell aggregation has been long known to facilitate metastatic potential of cancer cells. In addition, the presence of nitric oxide (NO) in cancer area may have a significant impact on aggregation behavior of the cells. We show herein that lung cancer H460 cells possessing high ability of anoikis resistance formed loose aggregates in detached condition. Importantly, NO treatment tightened the aggregates by enhancing cell-cell interaction via E-cadherin-dependent mechanism, and such E-cadherin contact increased anoikis resistance potential by up-regulating pro-survival signals of the cells including active ATP-dependent tyrosine kinase and extracellular-regulated protein kinases (ERK1/2). Since an increase of E-cadherin was frequently found in mesenchymal to epithelial transition (MET) process, we further tested the cells for MET markers and found that NO treatment of these cells significantly enhanced MET. As aggregation and MET of cancer cells may facilitate cancer metastasis by many means, the insights gained from the present study could benefit the deep understanding in the biology of cancer cell metastasis.
Chemical factors induce aggregative multicellularity in a close unicellular relative of animals.
Ros-Rocher N, Kidner R, Gerdt C, Davidson W, Ruiz-Trillo I, Gerdt J Proc Natl Acad Sci U S A. 2023; 120(18):e2216668120.
PMID: 37094139 PMC: 10161120. DOI: 10.1073/pnas.2216668120.
Influence of nitric oxide signaling mechanisms in cancer.
Ramirez-Patino R, Avalos-Navarro G, Figuera L, Varela-Hernandez J, Bautista-Herrera L, Munoz-Valle J Int J Immunopathol Pharmacol. 2022; 36:3946320221135454.
PMID: 36260949 PMC: 9585559. DOI: 10.1177/03946320221135454.
Ciccone V, Filippelli A, Bacchella C, Monzani E, Morbidelli L Cancers (Basel). 2022; 14(17).
PMID: 36077778 PMC: 9454450. DOI: 10.3390/cancers14174240.
Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review).
Salihi A, Al-Naqshabandi M, Khudhur Z, Housein Z, Hama H, Abdullah R Mol Med Rep. 2022; 26(1).
PMID: 35616143 PMC: 9178674. DOI: 10.3892/mmr.2022.12749.
Jang E, Sung J, Yoo H, Jang H, Shim J, Oh E Cancers (Basel). 2021; 13(2).
PMID: 33440835 PMC: 7826942. DOI: 10.3390/cancers13020247.